# Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial

*PRI Rank #6 · Topics and Trends in Most Cited Acute Myeloid Leukemia Research Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/acute-myeloid-leukemia-research/2026/rank-6*

| Field | Value |
| --- | --- |
| Rank | #6 |
| 18m citations | 80 |
| Journal | The Lancet Oncology |
| Year | 2024 |
| DOI | 10.1016/s1470-2045(24)00386-3 |
| Corresponding authors | Eunice S. Wang |
| Institution | Roswell Park Comprehensive Cancer Center, United States |

**Ranking page:** [Topics and Trends in Most Cited Acute Myeloid Leukemia Research Papers, Class of 2026](https://pri.pepkio.com/top-papers/acute-myeloid-leukemia-research/2026)

**Paper link:** [10.1016/s1470-2045(24)00386-3](https://doi.org/10.1016/s1470-2045(24)00386-3)

## Topics

Ziftomenib · Relapsed/refractory acute myeloid leukemia · KOMET-001 · Phase 1 clinical trial · multi-cohort study · Menin inhibitor · KMT2A rearrangement · NPM1 mutation · dose escalation · maximum tolerated dose · differentiation syndrome · Complete remission (CR) · Measurable residual disease (MRD) · pharmacokinetics · target engagement · MEIS1 suppression · safety profile · adverse events

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Acute Myeloid Leukemia Research Papers, Class of 2026. https://pri.pepkio.com/top-papers/acute-myeloid-leukemia-research/2026. Accessed 2026-07-31.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```